Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics Inc (NQ: ALLO )

3.090 +0.010 (+0.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Allogene Therapeutics Earnings Preview
Allogene Therapeutics (NASDAQ:ALLO) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement.... 
Via Benzinga
FDA Lifts Clinical Hold On Allogene's CAR-T Trials
The FDA has lifted the hold on Cellectis SA's (NASDAQ: CLLS) licensed partner, Allogene Therapeutics Inc (NASDAQ: ALLO) clinical trials. The... 
Via Benzinga
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The market value of their outstanding shares is at $3.7... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Arena Pharmaceuticals (NASDAQ:ARNA... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-... 
Via Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
Being First Is Not Enough For Crispr Therapeutics
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. 
Via InvestorPlace
Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call Transcript
ALLO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
2 Top Healthcare Stocks That Could Be Bought Out in 2022
These two novel-drug makers could be top takeover targets next year. 
Via The Motley Fool
Exposures COVID-19
Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review
It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields. 
Via Investor's Business Daily
Exposures Fossil Fuels
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
A key gene-editing readout had Cathie Wood shuffling her portfolio. 
Via The Motley Fool
Exposures Product Safety
Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments
Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend... 
Via FinancialNewsMedia
Exposures COVID-19
50 Biggest Movers From Yesterday
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
Crispr is planning to begin a registrational test in the first quarter of 2022. 
Via Investor's Business Daily
What 5 Analyst Ratings Have To Say About Allogene Therapeutics
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed ... 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
35 Biggest Movers From Friday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.24% to 34,835.06 while the NASDAQ fell 0.13% to 14,635.04. The S&P also rose, gaining 0.13% to 4,405.69. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks
The broader market was mixed on Friday. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Allogene Therapeutics Stock Is Getting Hammered Today
A possible safety issue is crushing the biotech's shares today. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge
Midway through trading Friday, the Dow traded down 0.06% to 34,734.52 while the NASDAQ fell 0.25% to 14,617.60. The S&P also fell, dropping 0.08% to 4,396.09. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Where Allogene Therapeutics Stands With Analysts
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.